Calidi Biotherapeutics Q1 net loss $7.2M, cash $1.4M after $6.1M offering

Calidi Biotherapeutics, Inc.

2024-Q1 EPS reported -$0.20

Net loss $7.2M ($0.20/share) vs $6.5M ($0.75/share) Q1 2023; R&D $2.7M, G&A $4.0M.
Cash & restricted cash $1.4M at Mar 31, 2024, down from $2.1M at Dec 31, 2023.
Closed public offering of 15.2M shares/warrants, gross proceeds $6.1M.
Will present three posters at ASCO 2024 including Phase 1 update for CLD-101 in recurrent high-grade glioma.
CEO states focus on raising additional capital and cost cutting; Phase 1 initiation with Northwestern expected Q3 2024 subject to capital.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Calidi Biotherapeutics, Inc. reported three months ended March 31, 2024 results: net income $7.2 million, EPS $0.20 per share.

Period: three months ended March 31, 2024
Net income: $7.2 million
EPS: $0.20 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $7.2 million, or $0.20 per share, for the three months ended March 31, 2024

View on SEC.gov

1443 earnings releases filed in the last 30 days. Browse all earnings releases →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.